The aim of the present work was to perform a systematic review of drug metabolism, transport, pharmacokinetics, and DDI data available in the NDAs approved by the FDA in 2013, using the University of Washington Drug Interaction Database, and to highlight significant findings. Among 27 NMEs approved, 22 (81%) were well characterized with regard to drug metabolism, transport, or organ impairment, in accordance with the FDA drug interaction guidance (2012) and were fully analyzed in this review. In vitro, a majority of the NMEs were found to be substrates or inhibitors/inducers of at least one drug metabolizing enzyme or transporter. However, in vivo, only half (n = 11) showed clinically relevant drug interactions, with most related to the NMEs as victim drugs and CYP3A being the most affected enzyme. As perpetrators, the overall effects for NMEs were much less pronounced, compared with when they served as victims. In addition, the pharmacokinetic evaluation in patients with hepatic or renal impairment provided useful information for further understanding of the drugs' disposition. Dallas, Texas. dx.doi.org/10.1124/dmd.114.060392.
Introduction
Pharmacokinetic drug interactions can lead to severe side effects and can result in early termination of development or withdrawal of drugs from the market. Thus, determining the risk of clinically significant drugdrug interactions (DDIs) during the development of a new molecular entity (NME) is critical. With the advancement of pharmaceutical research and novel drug discoveries, it is becoming increasingly challenging for pharmaceutical companies to design safer and more effective drug molecules, as well as to devise new approaches circumventing DDIs mediated by various enzymes and transporters (Huang et al., 2008) . Over the past several years, the pharmaceutical regulatory agencies in the United States [Food and Drug Administration (FDA)] and Europe [European Medicines Agency (EMA)] have issued a series of guidance documents for in vitro and in vivo drug interaction studies that must be conducted during drug development (http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf; http://www.regsource.com/Regulatory_Links/Regs_Laws___Forms/Federal_ Reg_by_Area/Toxicology/toxicology.html; http://www.fda.gov/OHRMS/ DOCKETS/98fr/06d-0344-gdl0001.pdf; http://www.fda.gov/downloads/ drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/ 2012/07/WC500129606.pdf). These guidelines include assessment of the DDI potential of NMEs, using individual preclinical evaluations and clinical pharmacology studies, with recommended probe substrates and specific inhibitors/inducers of drug metabolizing enzymes and transporters. Based on the results of these evaluations, one can then predict the interaction potential of the NME with a series of drugs that are likely to be coadministered (evidence-based theoretical interactions). The guidance documents reflect a drive by regulatory authorities to harmonize approaches and study designs to allow for better assessment and comparison of different NMEs and to facilitate consistent communication of drug interaction risks to healthcare providers through drug labeling. Both the FDA and EMA documents emphasize the use of an integrated and mechanistic approach to evaluate DDIs and, as such, have dramatically changed the outlook for assessing the potential incidence of clinically significant interactions in pre-and postmarketing stages (Huang et al., 2008; Zhao et al., 2012) .
This review encompasses an overall detailed analysis of the preclinical and clinical enzyme-and transporter-mediated DDIs observed for new drug applications (NDAs) approved by the FDA in 2013, highlighting the main mechanistic findings and discussing their clinical relevance. The analysis was performed using the University of Washington Drug Interaction Database (DIDB) drug interactions, pharmacogenetics, and organ impairment modules (http://www.druginteractioninfo.org). All of the parameters were directly extracted from the database, and the changes in mean AUC values are presented in this review. The DIDB data were curated from a thorough review of the NDA approval packages, including, but not limited to, the product labels and clinical pharmacology and biopharmaceutics reviews for each of the NMEs, available at the FDA approved drugs website (Drugs@FDA, http://www.accessdata.fda. gov/scripts/cder/drugsatfda/). The analysis used a mechanistic approach for evaluating DDIs reported for the individual NMEs based on the decision criteria recommended by the most recent FDA drug interaction guidance document (FDA, 2012) . In addition to the individual enzyme and transporter preclinical and clinical studies reported in the NDAs, studies looking at mechanisms for enzyme-transporter interplay, as well as those conducted in diseased populations (i.e., hepatic and renal impairment), were also systematically analyzed. The metrics used for evaluation of clinical studies is the area under the curve (AUC) ratio, defined as AUC inhibited or induced /AUC control , with a clinically significant interaction resulting in an AUC ratio $2. In addition, important or significant labeling modifications or recommendations were also noted. In 2013, a total of 25 NDAs and 2 biologic license applications (BLAs) were approved by the FDA. A summary of the NDA/BLAs, including DDIs, pharmacogenetics, and organ impairment studies, as well as therapeutic classes and approval dates, is presented in Table 1 , with the chemical structures presented in Supplemental Table 1 . Eight of these (30%) were cancer treatments, including four kinase inhibitors, making oncology the most represented therapeutic area. Among the 27 NMEs approved in 2013, 22 (81%) had drug metabolism or transporter data available, and therefore were fully analyzed in this review [18 (67%) provided hepatic impairment (HI) and/or renal impairment (RI) studies]. The NDAs without those studies were not evaluated in this review and comprised radioactive diagnostic or therapeutic agents, as well as a cytolytic antibody.
Preclinical Drug Interaction Data
Metabolism and Enzyme-Mediated DDIs. The most recent drug interaction guidance released by the FDA has focused on criteria that would streamline the evaluation procedure for drug metabolizing enzymes, highlighting decision criteria for evaluation of NMEs as substrates, inhibitors, or inducers of clinically important cytochrome P450 enzymes, including: CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A. Furthermore, with the growing interest in studying DDIs mediated by UGTs, the guidance also highlights the decision criteria for in vitro and in vivo studies to evaluate the same for UGT1A1, 1A3, 1A4, 1A6, 1A9, 2B7, and 2B15 (FDA, 2012) .
In accordance with the guidance, the metabolic profile of the NMEs approved in 2013 was well characterized from in vitro studies using recombinant enzymes and human liver tissues such as human liver microsomes (HLMs) or human hepatocytes. Twenty-three compounds were shown to be metabolized by at least one enzyme (in the case of combination drugs, such as fluticasone and vilanterol, both compounds were counted if the sponsor tested the components individually), although the majority of compounds were primarily metabolized by cytochrome P450s (Table 2) . Not surprisingly, CYP3A4/5 was shown to metabolize the largest number of NMEs in vitro (n = 17, 77% of NMEs evaluated), although not necessarily as the major enzyme contributing to the drug's metabolism. In vivo studies further confirmed that 10 of these compounds (45% of NMEs evaluated) were CYP3A substrates, with systemic exposure increases of greater than 20% (FDA cut-off: 25%), when coadministered with potent or moderate CYP3A inhibitors, resulting in the following maximum AUC ratios: ibrutinib, 23.9; simeprevir, 6.5; riociguat, 2.5; macitentan, 2.3; vilanterol (in combination with umeclidinium), 1.9; dabrafenib, 1.6; fluticasone (in combination with vilanterol), 1.4; ospemifene, 1.4; vortioxetine, 1.3; and dolutegravir, 1.2. Inhibition of transporters, especially P-glycoprotein (P-gp), might also contribute to the increased exposure of some of the drugs that were shown also to be P-gp substrates (reviewed in the next section). The highest AUC ratio was observed for ibrutinib (over 20) with concurrent use of ketoconazole (400 mg once daily for 6 days), indicating the primary role of CYP3A in the disposition of the drug. Accordingly, contraindications of strong and moderate CYP3A inhibitors and strong CYP3A inducers were clearly addressed in the product label (FDA, 2013j). The next largest interaction observed was simeprevir, with an AUC ratio over 5 when coadministered with the CYP3A inhibitor erythromycin (500 mg three times a day for 7 days), suggesting simeprevir as a sensitive substrate of CYP3A. On the basis of these results, the potential for DDIs with moderate or strong inducers or inhibitors of CYP3A must be considered before and during treatment with this drug, as indicated in the product label (FDA, 2013r) . Other cytochrome P450 isoforms, such as CYP2D6, 2C19, 2C9, and 2C8 were involved in the metabolism of 8, 7, 4, and 3 NMEs, respectively ( Fig. 1A ).
In addition, some NMEs were primarily metabolized by non-cytochrome P450 enzymes (Table 2) . For example, sofosbuvir, as a prodrug, is metabolically activated through pathways involving sequential hydrolysis by human cathepsin A (CatA) or carboxylesterase 1 (CES1) and subsequent phosphorylation to the active triphosphate compound by kinases. Additionally, the major metabolic pathway of three NMEs, canagliflozin, dolutegravir, and bazedoxifene, is through phase II glucuronidation by UGT2B7/1A9, UGT1A1, and UGT1A1/1A10, respectively. In vivo, in the case of canagliflozin, its systemic exposure (AUC) was slightly increased by 21% when coadministered with the general UGT inhibitor probenecid. Similarly, for dolutegravir, the concurrent use of the UGT1A1 inhibitor atazanavir significantly increased the AUC by 91%.
When NMEs were considered as perpetrators, the potential to inhibit drug metabolizing enzymes was investigated in vitro using HLMs or cDNA-expressed enzymes to determine the inhibitory mechanisms (e.g., reversible or time-dependent inhibition) and inhibition potency.
Seventeen (77%) NMEs inhibited at least one cytochrome P450 enzyme (Table 3, Fig. 1B) , with the most affected enzymes being CYP3A4 (n = 11), 2C9 (n = 10), 2C19 (n = 10), 2C8 (n = 9), and 2D6 (n = 8). Simeprevir was also found to inhibit UGT1A1 weakly in vitro. With regard to the inhibitory mechanism, most inhibitory drug interactions with cytochrome P450 enzymes are reversible with the exception of mertansine, the active component of ado-trastuzumab emtansine, an antibody-drug conjugate for the treatment of cancer, which showed time-dependent inhibition of CYP3A4 with an IC 50 of 0.16 mM after preincubation, whereas no inhibition was observed under coincubation conditions up to 0.678 mM. However, no further in vitro studies were available to obtain the time-dependent inhibition parameters.
In line with the drug interaction guidance (FDA, 2012), a basic model was first applied by estimating intrinsic clearance values (R) in the absence and presence of an inhibitor (or inducer) using both in vitro and clinical pharmacokinetic data to determine if an in vivo DDI study was warranted. On the basis of the R 1 values (for reversible inhibition), the majority of the in vitro inhibitory interactions were not considered clinically relevant (R 1 # 1.1). Among drugs with R 1 . 1.1, in vivo studies with sensitive cytochrome P450 substrates found only two NMEs with positive enzyme inhibition, where simeprevir weakly inhibited intestinal but not hepatic CYP3A (oral midazolam, AUC ratio = 1.4), CYP1A2 (caffeine, AUC ratio = 1.3), and CYP2C19 (omeprazole, AUC ratio = 1.3), whereas alogliptin weakly inhibited CYP2D6 (dextromethorphan, AUC ratio = 1.3). More complex models, such as mechanistic static models and physiologically based pharmacokinetic (PBPK) models, were also well incorporated for some drugs in predicting the in vivo DDI risks. For example, canagliflozin showed positive inhibition of CYP2B6 (IC 50 = 16 mM) in vitro and a large R 1 value (2.51); however, a PBPK model showed no interaction with coadministration of the CYP2B6 probe bupropion, hence, no in vivo study was warranted. It should be noted that although bupropion is considered as the most sensitive CYP2B6 substrate, currently there are no sensitive CYP2B6 substrates available based on the FDA guidance classification (AUC ratio of at least 5-fold or decrease in oral clearance of 80% or more when coadministered with a known inhibitor) (FDA, 2012) .
In terms of enzyme induction potential, 21 NMEs were evaluated using human hepatocytes, and 6 (29%) were found to induce cytochrome P450 enzyme expression to some extent (Table 4) : alogliptin (CYP3A4), dabrafenib (CYP2B6/3A4), dolutegravir (PXR activator), macitentan (CYP3A4), ospemifene (CYP1A2/2B6/3A4), and trametinib (CYP2B6/3A4). In vivo, only dabrafenib (R 3 = 0.54) was found to be a moderate CYP3A inducer and to decrease the systemic exposure of the coadministered CYP3A probe substrate midazolam by 74 and 61% in AUC and C max , respectively. Interestingly, ospemifene, in addition to inducing CYP2B6 mRNA expression, also showed inhibition of the same enzyme in HLMs, and overall in vivo, the exposure of the CYP2B6 probe substrate bupropion was not significantly affected (AUC ratio = 0.83, FDA cut-off: 25%). In contrast, for the prodrug eslicarbazepine acetate, none of its pharmacologically active metabolites, including eslicarbazepine (main), (R)-licarbazepine, and oxcarbazepine, induced CYP3A when tested at concentrations up to 100 mg/ml (eslicarbazepine C max = 15 mg/ml) in the in vitro screenings performed by the sponsor. However, when tested in vivo, coadministration of eslicarbazepine acetate decreased the exposure of simvastatin by 50% and the oral contraceptive ethinyl estradiol by 31%, which may be due to CYP3A induction. Warfarin exposure was also decreased by 21%, which may be reflective of possible CYP2C9 induction. In vitro, eslicarbazepine was also found not to induce CYP1A, CYP2C19, UGTs, or sulfotransferase by the sponsor. It should be noted that the magnitude of induction from the positive controls used in these cytochrome P450 induction screenings were lower than expected. In addition, oxcarbazepine was previously reported to induce CYP3A mRNA expression as well as enzyme activity in human hepatocytes (Fahmi et al., 2010) .
In summary, regarding drug metabolizing enzymes, CYP3A was involved in the metabolism of the most NMEs in vitro (17 of 22), and 10 were further confirmed to be substrates of CYP3A in vivo. In addition, the largest DDI observed in vivo was caused by CYP3A inhibition, with ibrutinib being the victim drug. As perpetrators, 17 drugs (77%) showed positive inhibition or induction toward at least one enzyme in vitro. In contrast, in vivo, only three NMEs (simeprevir, alogliptin, and eslicarbazepine acetate) were found to be enzyme inhibitors and two NMEs (dabrafenib and eslicarbazepine acetate) to be enzyme inducers, highlighting the challenge of translating inhibition and induction data from in vitro to in vivo. The overall in vivo effect of NMEs as perpetrators was much less pronounced, with the largest AUC ratio less than 2, compared with when the NMEs served as victim drugs, where the largest AUC ratio observed was greater than 20. 
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1.03 5.9 j (CYP2C9) 1.06 6.6 j (CYP2C19) Transport and Transporter-Mediated DDIs. In addition to drug metabolizing enzymes, the recent guidance documents, in conjunction with the International Transporter Consortium, have advocated the importance of transporters as additional driving mechanisms for DDIs, along with aiding the enzyme-mediated DDI events Huang et al., 2010; Tweedie et al., 2013) . The previous FDA guidance (FDA, 2006 ) specifically named P-gp only as a transporter that NMEs should be screened against, whereas the most recent document adds six additional transporters to be considered: breast cancer resistance protein (BCRP), organic anion transporting polypeptides 1B1 and 1B3 (OATP1B1, OATP1B3), organic cation transporter 2 (OCT2), and organic anion transporters 1 and 3 (OAT1 and OAT3). This guidance document recommends that all NMEs should be screened as inhibitors for these seven transporters and also as substrates for P-gp and BCRP. Additionally, depending on the route of elimination, NMEs should be screened as substrates for the remaining five transporters (.25% renal excretion, or unknown-OAT1, OAT3, and OCT2; .25% biliary excretion, or unknown-OATP1B1, OATP1B3). Finally, other transporters, such as MRPs, multidrug and toxin extrusion transporters, and/or bile salt export pump should also be considered, when appropriate (FDA, 2012) .
Out of the 22 NDAs approved in 2013 that contain DDI studies, nearly all of them (n = 20) include some type of transporter study, which is reflective of the recent guidance document. Within those 20 NDAs, more than 120 in vitro transporter assays are described, screening compounds against a total of 16 transporters. Not surprisingly, P-gp was the most represented transporter, both in substrate and inhibition assays performed, as well as positive interactions identified. Although the most recent guidance document is still in draft form, and only recently released, the remaining transporters recommended therein were also well represented, along with the following additional transporters: multidrug resistance-associated protein 2 (MRP2), OCT1, OATP2B1, bile salt export pump, multidrug and toxin extrusion transporter 1, organic cation transporters, novel, 1 and 2 (OCTN1, OCTN2), sodium-taurocholate cotransporting polypeptide, and urate transporter 1.
With the exception of eslicarbazepine acetate and bazedoxifene, all of the NMEs were screened as substrates of P-gp and 12 were shown to be substrates in vitro (Table 2 ). In the case of eslicarbazepine acetate, in vivo drug interaction studies were preemptively performed with two known P-gp inhibitors, cyclosporine and verapamil, and no interaction was observed in either study. For bazedoxifene, in vitro screening studies have been published previously (Shen et al., 2010) , thus no studies were included in the filing. Out of the 12 positive P-gp in vitro results, 7 in vivo studies were performed, with the largest interaction observed in the case of sofosbuvir (AUC ratio = 3.6, when coadministered with cyclosporine). In addition to being a P-gp substrate, sofosbuvir was also one of the 4 compounds shown to be a BCRP substrate in vitro. As cyclosporine is also a BCRP inhibitor, BCRP may have contributed to the effect seen in the in vivo interaction study. The next largest interaction observed also involved sofosbuvir, with another NME, simeprevir. Both are antiviral treatments for hepatitis C and could be coadministered in patients, and both NMEs were shown to be P-gp substrates; however, only simeprevir was shown to be a P-gp inhibitor in vitro. An AUC ratio of 3.2 was observed for sofosbuvir when coadministered with simeprevir; however, at the time of NDA submission, the clinical study was still ongoing and comparisons were made to historical data.
Of the remaining NMEs tested as the victims in in vivo DDI studies, six were tested as P-gp substrates (afatinib, alogliptin, canagliflozin, riociguat, umeclidinium, and vilanterol) and two as OATP substrates (simeprevir and macitentan). With the exception of riociguat, all resulted in ,50% change in AUC with coadministration of the transporter inhibitor or inducer. Despite this, the product label for afatinib contains a warning that coadministration of P-gp inhibitors or inducers may alter afatinib exposure and the dose should be adjusted as necessary and if tolerated (FDA, 2013i). In the case of riociguat, there was a 150% increase in AUC when coadministered with ketoconazole. Although most of this is likely due to CYP3A inhibition, the sponsor postulates some of the effect could be due to inhibition of P-gp and/or BCRP, because riociguat was shown to be a substrate of both transporters in vitro. Therefore, the product label advises to consider starting at a lower dose of riociguat when strong CYP3A, P-gp, or BCRP inhibitors are coadministered (FDA, 2013a) .
With regard to inhibitory interactions, P-gp was again the most represented transporter, with seven NMEs shown to be inhibitors in vitro (Table 5) . Only one NME, trametinib, resulted in both [I] 1 /IC 50 and [I] 2 /IC 50 values below the guidance cut-off values (0.1 and 10, respectively), therefore no in vivo studies were warranted (FDA, 2012) . Another compound, vilanterol, present in two approved NDAs with fluticasone or umeclidinium, was shown to inhibit P-gp in vitro, although the IC 50 was estimated to be greater than 100 mM, and given that systemic concentrations of vilanterol are in the sub-nanomolar range, the [I] 1 /IC 50 value is far below 0.1. Moreover, as an orally inhaled drug, there is no expected gut interaction with P-gp. Two NMEs, canagliflozin and simeprevir, resulted in both [I] 1 /IC 50 and [I] 2 /IC 50 values greater than the cut-off values, warranting in vivo interaction studies. However, in vivo, only limited increases in digoxin AUC were observed when coadministered with canagliflozin (AUC ratio = 1.2) or simeprevir (AUC ratio = 1.4). The product label for both compounds reflects this, stating that patients taking digoxin concomitantly should be monitored appropriately (FDA, 2013r,k) .
In addition, three NMEs resulted in [I] 1 /IC 50 values less than 0.1 but [I] 2 /IC 50 values greater than 10 (vortioxetine, ibrutinib and afatinib). In the case of vortioxetine, the [I] 2 /IC 50 value was neither provided nor discussed in the NDA reviews and was calculated by the DIDB Editorial Team based on a 10 mg dose. For ibrutinib, instead of performing an in vivo interaction study, the sponsor used PBPK modeling to simulate ibrutinib drug absorption kinetics. The model predicted quick absorption, generally completed in less than 2.5 hours; therefore, by staggering the dose of a P-gp substrate and ibrutinib by at least 2.5 hours, the potential for an interaction could be minimized. The ibrutinib product label, however, does warn that coadministration of oral narrow therapeutic index P-gp substrates, such as digoxin, may result in increased blood concentrations of those compounds (FDA, 2013j) . Finally, in the case of afatinib, the sponsor submitted data from three clinical settings demonstrating no clinically relevant effects of afatinib on orally administered P-gp substrates, including digoxin, thus, no further in vivo studies were carried out. There were two NMEs where only in vivo (no in vitro) studies were performed with regard to P-gp inhibition-alogliptin and eslicarbazepine acetate. Both compounds had no effect on digoxin AUC (0.3 and 5.7% decrease, respectively). Fexofenadine, a substrate of P-gp and OATPs, was also used as a victim in an alogliptin in vivo DDI study where, in contrast, an effect was observed (although fairly small, AUC ratio of 1.26), which could be reflective of inhibition of P-gp, as well as OATPs.
Six NMEs were shown to inhibit OATP1B1 and/or 1B3 in vitro. Of those, only two had C max /IC 50 values above the FDA guidance cut-off of 0.1 (FDA, 2012)-dabrafenib and simeprevir (Table 6 ). In the case of dabrafenib, the sponsor evaluated the DDI risk using static mathematical models, as described in the FDA guidance, which resulted in R values equal to 1.0 for both transporters below the cut-off value of 1.25, suggesting that the DDI risk was minimal and an in vivo study was not warranted. For simeprevir, three in vivo studies were performed with simeprevir as a perpetrator using statins-atorvastatin, simvastatin (both also CYP3A and P-gp substrates), and rosuvastatin. The largest change in AUC, and, in fact, the largest change for any of the transporter-based in vivo inhibition studies, was with rosuvastatin where an AUC ratio of 2.8 was observed. For atorvastatin and simvastatin, the effect was marginally less, with AUC ratios equal to 2.2 and 1.7, respectively. Consequently, the product label for simeprevir advises careful monitoring of patients taking any statins, and particularly with rosuvastatin and atorvastatin not to exceed a daily dose of 10 or 40 mg statin per day, respectively, when coadministered with simeprevir (FDA, 2013r).
In summary, three NMEs were shown to be in vivo inhibitors of P-gp: alogliptin, canagliflozin, and simeprevir, with simeprevir also inhibiting OATP1B1 in vivo. In vitro, in contrast, 85% of NMEs showed a positive interaction with at least one transporter, either as a substrate or inhibitor. Only three NMEs showed no interaction with any transporter, and in all three cases, P-gp was the only transporter tested. These data indicate that when tested in vitro, many NMEs appear to be substrates or inhibitors of at least one transporter. However, this does not necessarily translate in vivo, and the clinical relevance of the transporter interaction may be minimal, especially when compared with the effect of drug metabolizing enzymes. Reasons for this may include extensive protein binding of drugs, resulting in low free circulating concentrations, as well as interplay between drug metabolizing enzymes and transporters, both of which have been reviewed recently (Benet, 2010; Giacomini et al., 2010; Chu et al., 2013) . For example, canagliflozin and simeprevir are both greater than 98% protein bound, whereas simeprevir is also a substrate and inhibitor of several cytochrome P450s, all of which may contribute to the moderate effects observed in the digoxin interaction studies mentioned earlier. In addition, with the exception of P-gp, for which the probe substrates or inhibitors used both in vivo and in vitro were fairly consistent among the NMEs, less consensus was observed regarding probe substrates and inhibitors for the other transporters, which may confound translation of in vitro data to the clinical setting. 
Downloaded from

Pharmacogenetic Studies
As documented in the FDA drug interaction guidance (FDA, 2012), comparative pharmacokinetic data in subjects with various enzyme genotypes may be used to identify metabolic pathways and estimate the possible extent of interactions. Two NMEs, dolutegravir and umeclidinium (in combination with vilanterol), provided pharmacogenetic analyses to evaluate the effect of the genetic status of primary enzymes on the pharmacokinetics of these drugs. In the case of dolutegravir, which is primarily metabolized by the polymorphic enzyme UGT1A1, with some contribution from CYP3A, the effect of the genetic status of UGT1A1 on dolutegravir pharmacokinetics was evaluated through a meta-analysis using samples (n = 89) collected from subjects with low (poor metabolizers, *28/*28, *28/*37, *37/*37), reduced (intermediate metabolizers, *1/*28, *1/*37, *28/*36, *36/*37), and normal (extensive metabolizers, EMs, *1/*1, *1/*36, *36/*36) UGT1A1 activity. The analysis showed that, compared with subjects with normal UGT1A1 activity, the AUC and C max increased by 30-50% and 20-30%, respectively, whereas clearance decreased by 20-30% in subjects with low and reduced UGT1A1 activity. According to the sponsor, as the therapeutic index of dolutegravir is wide and adverse effects are mild and not associated with higher exposures, the effect of UGT1A1 polymorphisms on dolutegravir exposure is not considered clinically significant, hence no dose adjustment is required for subjects with the UGT1A1 *28/*28 and *28/*37 genotypes (FDA, 2013y). The influence of CYP3A4, CYP3A5, and PXR variants on dolutegravir pharmacokinetics was also explored, and polymorphisms in CYP3A4/5 were found not to be associated with any pharmacokinetic changes. Similarly, for umeclidinium, which is mainly metabolized by the polymorphic enzyme CYP2D6, no clinically significant changes were observed in systemic exposure in CYP2D6 poor metabolizers compared with EMs (specific alleles not available in the NDA review). Overall, polymorphisms in primary metabolizing enzymes did not affect the pharmacokinetic parameters of the metabolized drugs to any clinically significant extent.
In addition, for simeprevir, although no genotyping data were available and no specific pharmacogenetic analyses were performed in the NDA reviews, it was discovered that in Phase 3 clinical trials subjects of East Asian ancestry (n = 14) had 3.4-fold higher exposure of simeprevir than the pooled Phase 3 population and that this higher exposure was associated with an increased frequency of adverse reactions. The increase in simeprevir exposure may be clinically relevant and is likely due to some as-yetunidentified genetic variation, therefore the product label states, "There are insufficient safety data to recommend an appropriate dose for patients of East Asian ancestry. The potential risks and benefits should be carefully considered prior to use in patients of East Asian ancestry" (FDA, 2013r). 
Clinically Significant Drug-Drug Interactions
Clinical DDI studies assess the exposure to a potential victim drug (AUC) with and without coadministration of the perpetrator, and the AUC ratio often constitutes the main quantitative DDI outcome measurement. However, assigning a clinical significance to the pharmacokinetic outcome can be complex. Additional information is often needed on the drug pharmacokinetic-pharmacodynamic relationship, the within-and between-individual variability in response, and the clinical context of patient status and underlying disease. Nevertheless, it is usually acknowledged that a twofold change in drug exposure will often trigger dosing recommendations, and thus an AUC ratio of 2 was considered in this analysis as a cut-off for further consideration. Overall, it was found that 10 of the 22 drugs analyzed (45%) had at least one metabolism-based in vivo DDI study with a change in exposure of clinical significance (AUC increase $2-fold or AUC decrease $50% for the affected drugs), with NMEs being mainly victim drugs. All clinically significant inhibition and induction results observed with NMEs as victims or perpetrators are presented in Tables 7 (inhibition) and 8 (induction).
For inhibition studies (Table 7) , alteration of CYP3A activity was the most common underlying mechanism, except for ospemifene and vortioxetine. For ospemifene, its exposure was increased by almost threefold when coadministered with the multi-cytochrome P450 inhibitor fluconazole (200 mg once daily for 8 days). Ospemifene is primarily metabolized by CYP3A, 2C9, and 2C19, each of these enzymes being responsible for approximately 40-50, 25, and 25% of its clearance, respectively, and fluconazole is known to inhibit all three of these enzymes. Of note, concurrent administration of the strong CYP3A inhibitor ketoconazole increased ospemifene AUC by only 1.4-fold, whereas coadministration of the CYP2C19 inhibitor omeprazole increased its exposure by 1.2-fold (FDA, 2013t) . In addition, ospemifene is also sensitive to cytochrome P450 induction, because concomitant dosing with rifampin decreased ospemifene AUC by 58% and C max by 51%. Coadministration of both fluconazole and rifampin is contraindicated with ospemifene (FDA, 2013t). As for vortioxetine, which is primarily metabolized by CYP2D6, coadministration of the strong CYP2D6 inhibitor bupropion (150 mg twice daily) increased vortioxetine exposure by 2.3-fold. A reduction in vortioxetine dose by half is recommended when a strong CYP2D6 inhibitor (bupropion, fluoxetine, paroxetine, or quinidine) is coadministered (FDA, 2013e) . Two NMEs, ibrutinib and simeprevir, were found to be sensitive substrates of CYP3A, with AUC ratios greater than five when coadministered with known CYP3A inhibitors (ketoconazole and erythromycin, respectively). For ibrutinib, based on the very large increase in AUC observed (over 20-fold) when coadministered with ketoconazole (400 mg once daily for 6 days), concomitant use of strong CYP3A inhibitors that are taken chronically is not recommended. Preliminary data also showed that the strong CYP3A inducer rifampin caused a 14-fold decrease in ibrutinib C max and a 12.5-fold decrease in ibrutinib AUC, therefore the concomitant use of strong CYP3A4 inducers should be avoided, because a dose adjustment cannot be recommended [there is, however, no specific recommendation when ibrutinib is coadministered with a weak or moderate inducer (FDA, 2013j)]. Simeprevir exposure was increased by 7.2-and 6.5fold when coadministered with the strong CYP3A4 inhibitor ritonavir and the moderate CYP3A4 inhibitor erythromycin, respectively. In addition, coadministration of the CYP3A inducers rifampin and efavirenz resulted in decreases in simeprevir exposure close to 50%. On the basis of these results, concomitant use of simeprevir with strong and moderate CYP3A inhibitors or inducers should be avoided (FDA, 2013r) .
Regarding clinical induction data, significant inductions were mainly related to NMEs as victim drugs and, in most cases, involved induction of CYP3A by known inducers (Table 8) . When NMEs were considered as perpetrators, two compounds were found to significantly induce CYP3A, dabrafenib and eslicarbazepine acetate. Dabrafenib significantly reduced the AUC of the sensitive CYP3A substrate midazolam by over 70%, whereas eslicarbazepine acetate decreased simvastatin exposure by 50%. Both drugs have recommendations in their labels regarding their possible inductive effect on coadministered drugs (FDA, 2013c,w) .
Finally, there were very few purely transporter-based drug interactions with over twofold changes in substrates exposure. Only the interaction between sofosbuvir (400 mg single dose) and cyclosporine (administered as a high single dose of 600 mg) was related to inhibition of P-gp and BCRP and yielded an increase in sofosbuvir AUC of almost fourfold. However, the exposure of the predominant circulating inactive metabolite (GS-331007) was unchanged, and considering sofosbuvir safety margins, the effect of cyclosporine on sofosbuvir pharmacokinetics was not considered clinically significant by the sponsor and no dose adjustment is required. Also of note, sofosbuvir plasma exposure was also increased by coadministration of simeprevir (150 mg once daily for 12 or 24 weeks), an inhibitor of P-gp (AUC ratio of 3.2, as previously discussed).
Overall, when a cut-off of twofold change in drug exposure was considered for clinical relevance, almost half of the NMEs analyzed had clinically significant DDIs, most of them related to the NMEs as victim drugs. Not surprisingly, the underlying mechanism for a large number of these interactions was inhibition or induction of CYP3A.
Hepatic and Renal Impairment Studies
Hepatic and renal impairment are important disease conditions to consider while evaluating the potential plasma exposure that a particular NME would achieve clinically. In addition, such organ impairment may overlap with different critical disease conditions (e.g., in cancer patients), or may be associated with patients in certain age groups (e.g., geriatrics). As such, individuals may be receiving a multitude of medications, and this could lead to more complex DDIs potentially occurring due to multiple mechanisms involving metabolism and/or transport. Moreover, depending on the severity of impairment of these eliminating organs (mild, moderate or severe), the probability and extent of these DDIs may be affected significantly. Therefore, it has become critical to assess the pharmacokinetics of NMEs in impaired populations in the pre-marketing drug development stages. For the purpose of this review, the major outcome measurement of the NMEs was the AUC change or AUC ratio (AUC impaired /AUC control ), studied using patients with HI or RI and healthy control populations. For this assessment, similar to the in vivo clinical significance evaluation, an AUC ratio of 2 was considered as a cut-off to systematically evaluate the NDAs for any dosing and labeling recommendations for the NMEs in question.
Among the 15 NMEs evaluated for HI studies, four demonstrated an AUC ratio greater than 2 in the HI patients versus normal controls. The highest AUC ratio (6.0) was observed for ibrutinib in the moderate HI population (Child-Pugh B). However, the ibrutinib label states that there was "insufficient data to recommend a dose in patients with baseline HI" and recommended that ibrutinib should be avoided in these patients (FDA, 2013j) . The next largest change in AUC was observed for simeprevir, showing 2.4-and 5.2-fold increases in AUC for moderate and severe HI patients, respectively. Although no dose recommendations have been provided for simeprevir in these patients, the label states that the potential risks and benefits of simeprevir should be carefully considered before the use in patients with moderate or severe HI (FDA, 2013r). Moreover, bazedoxifene (with conjugated estrogens) demonstrated AUC ratios of 3.6, 2.1, and 4.3 in patients with mild, moderate, and severe HI, respectively, and hence has been contraindicated in women with any known HI or disease (FDA, 2013g). The increases in AUC observed in HI patients may be attributed to the fact that these compounds all undergo extensive hepatic metabolism and have also shown high biliary excretion, with .80% being eliminated in the feces. Finally, sofosbuvir showed AUC ratios greater than 2 in both moderate and severe HI patients. However, considering its renal elimination pathway (discussed in the following RI section), no dose adjustment has been recommended for any HI patients (FDA, 2013v) .
With regard to RI studies, 4 out of 17 NMEs demonstrated an AUC ratio greater than 2 in RI patients versus normal controls. Gadoterate meglumine showed the largest effect in RI patients, with 3.5-and 9.3fold increases in AUC and 61.3 and 87.3% decreases in clearance in moderate and severe RI patients, respectively. These data are reflective of the elimination pathway of gadoterate meglumine, where renal clearance approximates total clearance. No dose adjustment was suggested for RI populations; however, the product label contains a black box warning for the risk of the life-threatening adverse event nephrogenic systemic fibrosis in patients with chronic severe kidney disease (FDA, 2013f) . The next largest change in AUC involved alogliptin, where AUC ratios of 2.0, 3.6, and 4.7 were observed in moderate, severe RI and the end-stage renal disease (ESRD) populations, respectively, consistent with the fact that almost 80% of alogliptin is eliminated renally. Accordingly, a dose adjustment is recommended for moderate and severe RI and ESRD patients (FDA, 2013q) . Sofosbuvir, as a prodrug, is eliminated approximately 80% through renal excretion in the form of metabolites. Mild increases in AUC (AUC ratios between 1.6 and 2.7) were observed for sofosbuvir in the mild, moderate, severe RI and ESRD populations. However, the AUC of main (inactive) metabolite, GS-331007, was found to increase by 5.5-fold in severe RI and 13.8-and 21.7-fold in ESRD 1 hour before and after dialysis, respectively. On the basis of these results, no dose adjustment is needed for patients with mild or moderate renal impairment. However, as the safety and efficacy of sofosbuvir has not been established in patients with severe RI or ESRD requiring hemodialysis, dosing recommendations have not been made for these populations (FDA, 2013v) . Similarly, the prodrug eslicarbazepine acetate is also primarily eliminated by renal excretion as eslicarbazepine (the main active metabolite) and its glucuronide conjugate, together accounting for more than 90% of total metabolites excreted in the urine. In RI patients, 1.6-, 2.1-, 2.5-, and 1.4-fold increases in eslicarbazepine AUC, as well as 37.9, 52.6, 60.6, and 28.9% decreases in clearance, were observed in mild, moderate, severe RI and ESRD, respectively. Hence, a dose reduction has been recommended in the product label for patients with moderate and severe RI (FDA, 2013c). Overall, 19 NMEs were assessed for the influence of HI or RI on drug pharmacokinetics. One NME, sofosbuvir, showed significant pharmacokinetic effects in both HI and RI populations (AUC ratio $2); however, because of the metabolism and excretion properties of the compound, no dose adjustments were recommended for either population. Six additional NMEs showed significant effects in the impaired population (3 for HI and 3 for RI), which resulted in contraindications for respective populations in 5 out of 6 product labels. These data illustrate the importance of studying drug pharmacokinetics in impaired populations, because the AUC ratios observed in HI or RI patients may be on the same order of magnitude as those observed in clinical drug interaction studies.
Conclusion
The evaluation of DDIs during the drug development process has profoundly changed over the past two decades, and an integrated and mechanistic approach to these studies is highly recommended. The results of the detailed analysis of NDA reviews for drugs that have been approved by the FDA in 2013 were generally consistent with current regulatory recommendations. The drug interaction profiles were well characterized using probe markers and known inhibitors and inducers of drug metabolizing enzymes. Moreover, as significant scientific efforts have focused on elucidating the mechanisms and clinical significance of drug transporters, many NMEs were also thoroughly evaluated for transporterbased DDIs. Additionally, a majority of NMEs were also assessed in hepatic or renal impaired populations. These evaluations show that, using the knowledge gained from dedicated preclinical and clinical studies, the most significant clinical drug interactions can be identified, allowing effective and targeted dosing recommendations to be made.
